Monday, January 16, 2012

Asenapine for manic depression launched in UK

Lundbeck has launched the first sublingual treatment for bipolar I disorder, also known as manic depression, in the UK.

Sycrest (asenapine) is a new type of antipsychotic that stabilises manic episodes and has been shown to cause less weight gain than standard antipsychotic drugs such as olanzapine.

The launch accompanies the publication of a study showing that over three-quarters of patients taking antipsychotics suffer unwanted weight gain, and nearly half consider their medication unsatisfactory.

Bipolar disorder affects an estimated 623,000 patients in the UK, including many high-performing professionals.

Posted via email from Jack's posterous

No comments: